Generation Bio Co. (GBIO)

NASDAQ: GBIO · IEX Real-Time Price · USD
5.08
+0.08 (1.60%)
At close: Mar 24, 2023, 4:00 PM
4.84
-0.24 (-4.72%)
After-hours: Mar 24, 2023, 7:58 PM EDT
1.6%
Market Cap 303.10M
Revenue (ttm) n/a
Net Income (ttm) -136.64M
Shares Out 59.67M
EPS (ttm) -2.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,589,628
Open 5.00
Previous Close 5.00
Day's Range 4.71 - 5.19
52-Week Range 3.40 - 9.59
Beta 1.95
Analysts Buy
Price Target 13.26 (+161.02%)
Earnings Date May 4, 2023

About GBIO

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 12, 2020
Employees 150
Stock Exchange NASDAQ
Ticker Symbol GBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for GBIO stock is "Buy." The 12-month stock price forecast is $13.26, which is an increase of 161.02% from the latest price.

Price Target
$13.26
(161.02% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Generation Bio, Moderna announce collaboration

Shares of Generation Bio Co. GBIO, -0.51% jumped about 28% premarket trading on Thursday after the company announced a collaboration with Moderna Inc. MRNA, -2.58% to to develop novel nucleic acid the...

Other symbols: MRNA
1 day ago - Market Watch

Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines

Collaboration will extend the applications of each company's platform through discovery and development of novel lipid nanoparticles using Generation Bio's proprietary stealth cell-targeted lipid nano...

Other symbols: MRNA
1 day ago - Accesswire

Generation Bio to Participate in the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...

3 days ago - GlobeNewsWire

Generation Bio to Present at the 43rd Annual Cowen Healthcare Conference

CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced...

3 weeks ago - GlobeNewsWire

Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results

— Company expects to announce data for Factor VIII expression in non-human primates in 2023

1 month ago - GlobeNewsWire

Generation Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...

2 months ago - GlobeNewsWire

Can Generation Bio Co. (GBIO) Climb 184% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 183.8% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable...

3 months ago - Zacks Investment Research

Wall Street Analysts Think Generation Bio Co. (GBIO) Could Surge 176%: Read This Before Placing a Bet

The consensus price target hints at a 176% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

4 months ago - Zacks Investment Research

Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results

Cash balance of $301.2M expected to fund operations into 2025 Cash balance of $301.2M expected to fund operations into 2025

5 months ago - GlobeNewsWire

Generation Bio to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announc...

6 months ago - GlobeNewsWire

Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer

CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announc...

6 months ago - GlobeNewsWire

Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates

Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -4.76% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results

Cash balance of $312.2M expected to fund operations into 2025 Cash balance of $312.2M expected to fund operations into 2025

8 months ago - GlobeNewsWire

Generation Bio to Present at the 2022 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...

8 months ago - GlobeNewsWire

Generation Bio Appoints Dannielle Appelhans to Its Board of Directors

CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...

8 months ago - GlobeNewsWire

Wall Street Analysts See a 174% Upside in Generation Bio Co. (GBIO): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 173.7% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable...

9 months ago - Zacks Investment Research

Generation Bio to Present at the 2022 Jefferies Healthcare Conference

CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...

10 months ago - GlobeNewsWire

Generation Bio Co. (GBIO) Reports Q1 Loss, Lags Revenue Estimates

Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -17.31% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Generation Bio Reports Business Highlights and First Quarter 2022 Financial Results

Company continues to optimize cell-targeted lipid nanoparticle (ctLNP) delivery system for nonviral genetic medicine applications in liver, retina and vaccines

11 months ago - GlobeNewsWire

Generation Bio to Participate in 21st Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announc...

1 year ago - GlobeNewsWire

Generation Bio Co. (GBIO) Upgraded to Buy: Here's Why

Generation Bio Co. (GBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

How Much Upside is Left in Generation Bio Co. (GBIO)? Wall Street Analysts Think 505%

The consensus price target hints at a 504.9% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...

1 year ago - Zacks Investment Research

Generation Bio to Participate in 42nd Annual Cowen Health Care Conference

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announc...

1 year ago - GlobeNewsWire

Generation Bio Outlines 2022 Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

Well-capitalized with $375.1 million at the end of 2021, funding planned operations into 2024 Well-capitalized with $375.1 million at the end of 2021, funding planned operations into 2024

1 year ago - GlobeNewsWire

Generation Bio Promotes Antoinette Paone, M.S., MBA to Chief Operating Officer

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...

1 year ago - GlobeNewsWire